These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

570 related articles for article (PubMed ID: 19952121)

  • 1. Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer.
    Bao R; Lai CJ; Wang DG; Qu H; Yin L; Zifcak B; Tao X; Wang J; Atoyan R; Samson M; Forrester J; Xu GX; DellaRocca S; Borek M; Zhai HX; Cai X; Qian C
    Mol Cancer Ther; 2009 Dec; 8(12):3296-306. PubMed ID: 19952121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.
    Smith DL; Acquaviva J; Sequeira M; Jimenez JP; Zhang C; Sang J; Bates RC; Proia DA
    Target Oncol; 2015 Jun; 10(2):235-45. PubMed ID: 25077897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy.
    Bao R; Lai CJ; Qu H; Wang D; Yin L; Zifcak B; Atoyan R; Wang J; Samson M; Forrester J; DellaRocca S; Xu GX; Tao X; Zhai HX; Cai X; Qian C
    Clin Cancer Res; 2009 Jun; 15(12):4046-57. PubMed ID: 19509149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer.
    Ono N; Yamazaki T; Tsukaguchi T; Fujii T; Sakata K; Suda A; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
    Cancer Sci; 2013 Oct; 104(10):1346-52. PubMed ID: 23863134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
    Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
    Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.
    Qu Y; Wu X; Yin Y; Yang Y; Ma D; Li H
    J Exp Clin Cancer Res; 2014 Jun; 33(1):52. PubMed ID: 24939055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
    Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S
    Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer.
    Wang M; Zhao J; Zhang LM; Li H; Yu JP; Ren XB; Wang CL
    J Cancer Res Clin Oncol; 2012 Dec; 138(12):2069-77. PubMed ID: 22821179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.
    Zhang Y; Yao K; Shi C; Jiang Y; Liu K; Zhao S; Chen H; Reddy K; Zhang C; Chang X; Ryu J; Bode AM; Dong Z; Dong Z
    Oncotarget; 2015 Dec; 6(42):44274-88. PubMed ID: 26517520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of multiple signaling pathways by the Hsp90 inhibitor SNX-2112 in EGFR resistance models as a single agent or in combination with erlotinib.
    Rice JW; Veal JM; Barabasz A; Foley B; Fadden P; Scott A; Huang K; Steed P; Hall S
    Oncol Res; 2009; 18(5-6):229-42. PubMed ID: 20225761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
    Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
    Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer.
    Venkatesha VA; Joshi A; Venkataraman M; Sonawane V; Bhatia D; Tannu P; Bose J; Choudhari S; Srivastava A; Pandey PK; Lad VJ; Sangana R; Ahmed T; Damre A; Deore V; Sahu B; Kumar S; Sharma S; Agarwal VR
    Mol Cancer; 2014 Dec; 13():259. PubMed ID: 25466244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines.
    Holland WS; Chinn DC; Lara PN; Gandara DR; Mack PC
    J Cancer Res Clin Oncol; 2015 Apr; 141(4):615-26. PubMed ID: 25323938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
    Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A
    Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
    Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
    PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells.
    Wu DW; Chen TC; Huang HS; Lee H
    Cell Death Dis; 2016 Jun; 7(6):e2290. PubMed ID: 27362807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.
    Formisano L; D'Amato V; Servetto A; Brillante S; Raimondo L; Di Mauro C; Marciano R; Orsini RC; Cosconati S; Randazzo A; Parsons SJ; Montuori N; Veneziani BM; De Placido S; Rosa R; Bianco R
    Oncotarget; 2015 Sep; 6(28):26090-103. PubMed ID: 26325669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
    Naumov GN; Nilsson MB; Cascone T; Briggs A; Straume O; Akslen LA; Lifshits E; Byers LA; Xu L; Wu HK; Jänne P; Kobayashi S; Halmos B; Tenen D; Tang XM; Engelman J; Yeap B; Folkman J; Johnson BE; Heymach JV
    Clin Cancer Res; 2009 May; 15(10):3484-94. PubMed ID: 19447865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
    Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
    Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.
    Wang CY; Chao TT; Chang FY; Chen YL; Tsai YT; Lin HI; Huang YC; Shiau CW; Yu CJ; Chen KF
    Lung Cancer; 2014 Aug; 85(2):152-60. PubMed ID: 24954871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.